Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) CEO Sells $627,198.00 in Stock

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Get Free Report) CEO Brian Goff sold 18,700 shares of the business's stock in a transaction on Tuesday, June 24th. The shares were sold at an average price of $33.54, for a total transaction of $627,198.00. Following the completion of the transaction, the chief executive officer now owns 105,401 shares of the company's stock, valued at approximately $3,535,149.54. This represents a 15.07% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Agios Pharmaceuticals Stock Performance

Shares of NASDAQ:AGIO traded up $0.94 during midday trading on Thursday, reaching $33.65. 274,744 shares of the company's stock traded hands, compared to its average volume of 653,135. The company has a fifty day simple moving average of $31.03 and a two-hundred day simple moving average of $32.38. Agios Pharmaceuticals, Inc. has a 1 year low of $23.42 and a 1 year high of $62.58. The company has a market cap of $1.95 billion, a P/E ratio of 2.99 and a beta of 0.73.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The biopharmaceutical company reported ($1.55) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.80) by $0.25. Agios Pharmaceuticals had a net margin of 1,798.26% and a negative return on equity of 2.75%. The business had revenue of $8.73 million for the quarter, compared to the consensus estimate of $9.86 million. As a group, research analysts forecast that Agios Pharmaceuticals, Inc. will post -6.85 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. boosted its holdings in Agios Pharmaceuticals by 1.5% in the 4th quarter. Vanguard Group Inc. now owns 5,631,321 shares of the biopharmaceutical company's stock worth $185,045,000 after buying an additional 85,339 shares during the last quarter. Erste Asset Management GmbH lifted its position in shares of Agios Pharmaceuticals by 10.9% in the first quarter. Erste Asset Management GmbH now owns 2,229,900 shares of the biopharmaceutical company's stock valued at $65,439,000 after acquiring an additional 220,000 shares in the last quarter. Jefferies Financial Group Inc. purchased a new position in shares of Agios Pharmaceuticals in the fourth quarter valued at approximately $49,290,000. Frazier Life Sciences Management L.P. boosted its stake in shares of Agios Pharmaceuticals by 2.5% in the fourth quarter. Frazier Life Sciences Management L.P. now owns 1,069,754 shares of the biopharmaceutical company's stock worth $35,152,000 after acquiring an additional 25,600 shares during the last quarter. Finally, Fisher Asset Management LLC increased its position in shares of Agios Pharmaceuticals by 12.3% during the fourth quarter. Fisher Asset Management LLC now owns 960,661 shares of the biopharmaceutical company's stock worth $31,567,000 after purchasing an additional 105,333 shares in the last quarter.

Analysts Set New Price Targets

A number of research analysts have weighed in on the stock. Scotiabank cut their price objective on shares of Agios Pharmaceuticals from $74.00 to $71.00 and set a "sector outperform" rating for the company in a report on Friday, May 2nd. Wall Street Zen cut Agios Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Monday, May 19th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and five have given a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $58.60.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.